In June 2018, Remap Consulting had the pleasure of attending the annual National Institute of Health...
Read moreAt the current rate, annual deaths due to AMR is expected to reach 10 million by 2050 globally, with...
Read moreThe aim of this study was to determine the impact of delivery device reducing drug wastage.
Read moreDevelopment and implementation of the optimum price submission strategy for a product in the EU.
Read moreTo determine if there is a difference between incremental cost-effectiveness ratios (ICERs) in oncol...
Read moreIn the current climate of tighter budgetary controls and greater price scrutiny, a uniform pricing s...
Read moreOver the last year, the European Commission (EC) has been consulting on multiple scenarios for HTA h...
Read moreThe development of gene therapies represents a new frontier of science, with the potential to help p...
Read moreSince 2004, opportunity cost has been reflected in NICE's appraisal process through the specificatio...
Read moreThis study investigates NICE evaluations of new cancer indications and legacy CDF indications (not p...
Read more